Advancing TAVI practice

Session comprising selected EuroPCR 2026 late-breaking trials submissions

Anchorperson: J. Byrne

Spokesperson: T. Nazif

Summary

Advancing TAVI practice is the focus of this session, addressing antiplatelet therapy choices, novel transcatheter treatments for pure aortic regurgitation, early hemodynamic valve deterioration as a prognostic marker, prosthesis-patient mismatch in redo-TAVI, pioneering valve-in-mechanical valve interventions, and comprehensive core-lab evaluation of implantation depth and clinical outcomes.

Presentations available when logged in:

Aspirin vs. clopidogrel as single antiplatelet therapy after TAVI
Treatment of pure aortic regurgitation with a dedicated transcatheter heart valve vs. surgery: first results of EROICA
Early hemodynamic valve deterioration as a new prognostic marker after TAVI
Prosthesis-patient mismatch following redo-TAVI: insights from the prospective ReTAVI registry
First-in-human transcatheter valve-in-mechanical valve using disc dislodgement and extraction

Your free My PCR account will enable you to:

Become a PCR Companion
Access slide presentations from PCR Courses
Watch session videos and LIVE cases
Discuss cases with your peers
Submit and register for PCR Courses
Register for and view PCR Webinars
Read a selection of articles in EuroIntervention
And more…

Advancing TAVI practice

Session comprising selected EuroPCR 2026 late-breaking trials submissions

Log in or create account for free